Poland· PL-100199464
Neupro
A rotigotine product containing rotigotinum, registered in Poland by UCB Pharma S.A.. The same ATC class is registered in 18 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Rotigotine is registered in 18 of 19 countries.
Countries holding a registration under ATC N04BC09 (rotigotine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Rotigotine · ATC N04BC09
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rotigotine costs, country by country.
Normalised to the WHO defined daily dose (6 mg), the median price runs from $0.77 in Czechia to $4.34 in Switzerland — a ×5.6 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rotigotine · price per daily dose (6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$4.34
- CZ Czechia$0.77
The record
At a glance
URPL (Poland)- Active substance
- Rotigotinum
- Manufacturer
- UCB Pharma S.A.
- Country
- Poland (PL)
- ATC code
- N04BC09
- ATC class
- Rotigotine
- Defined daily dose
- 6 mg, TD
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 9
- gtin05909990664863
- gtin05909990664870
- gtin05909990664887
- gtin05909990664894
- gtin05909990664900
- gtin05909990664931
- gtin05909990664948
- gtin05909990664955
- gtin05909990664962
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
58 interactions on record for rotigotine.
Graded by severity as the source publishes them — 58 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rotigotine · interactions on record
58 records
- 58 moderate
Most severe, free to view
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- DronabinolA04AD10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rotigotine in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNEUPROUCB Pharma SA, Brusel
- BelgiumLeganto 3 mg/24 hUCB
- SpainKINPARLEV 3 MG/24 H PARCHE TRANSDERMICO EFGOrion Corporation
- United StatesNeuproUCB, Inc.
- NetherlandsNeupro 3 mg/24h, pleister voor transdermaal gebruikUCB Pharma S.A.
- United KingdomNeupro 1mg/24hours transdermal patchesUCB Pharma Ltd
- FinlandKinparlevOrion Corporation
- SwedenKinparlev 1 mg/24 timmar DepotplåsterOrion Corporation
Authorised across Europe · EMA
The same active substance is authorised in 16 EEA countries. Names it is sold under:
- Austria · Kinparlev, Rotigotin Gebro
- Germany · Rotigotin Luye, Rotigotin Neuraxpharm
- Denmark · Kinparlev, Rotigotine Medical Valley
- Spain · Dariante
- Finland · Kinparlev, Rotigotine Medical Valley
- France · Rotigotine Arrow
- Greece · Kinparlev
- Iceland · Neupro, Rotigotine Medical Valley
- Italy · Rotigotina Doc
- Liechtenstein · Neupro
- Luxembourg · Rotigotin Luye
- Netherlands · Rotigotine Medical Valley, Rotigotine Xiromed
- Norway · Kinparlev, Neupro
- Portugal · Kinparlev, Rotigotina Generis
- Romania · Kinparlev
- Sweden · Kinparlev, Rotigotine Medical Valley
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2dc1b9c6-55f2-439b-adf9-81a6aaa8e86a GET /v1/drugs/2dc1b9c6-55f2-439b-adf9-81a6aaa8e86a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "System transdermalny, plaster",
"source": "urpl",
"strength": "3 mg/24 h",
"packaging": "05909990664863 ¦ Rp ¦ EU/1/05/331/047 ¦ 45913\n7 plastrów\n05909990664870 ¦ Rp ¦ Skasowane ¦ EU/1/05/331/048 ¦ 45914\n20 plastrów\n05909990664887 ¦ Rp ¦ EU/1/05/331/049 ¦ 45915\n28 plastrów\n05909990664894 ¦ Rp ¦ EU/1/05/331/050 ¦ 45916\n30 plastrów\n05909990664900 ¦ Rp ¦ Skasowane ¦ EU/1/05/331/051 ¦ 45917\n56 plastrów\n05909990664931 ¦ Rp ¦ Skasowane ¦ EU/1/05/331/052 ¦ 45918\n60 plastrów\n05909990664948 ¦ Rp ¦ EU/1/05/331/053 ¦ 45919\n84 plastry\n05909990664955 ¦ Rp ¦ Skasowane ¦ EU/1/05/331/054 ¦ 45920\n90 plastry\n05909990664962 ¦ Rp ¦ Skasowane ¦ EU/1/05/331/055 ¦ 45921\n100 plastrów\nRp ¦ EU/1/05/331/058 ¦ 125993\n14 plastrów",
"substance": null,
"common_name": "Rotigotinum",
"pl_product_id": "100199464",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about rotigotine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.